Researchers from Rochester, Minn.-based Mayo Clinic analyzed outcomes among COVID-19 patients who were fully vaccinated and received one of the following antibodies: Eli Lilly’s bamlanivimab, Eli Lilly’s combination of bamlanivimab and etesevimab, or Regeneron’s combination of casirivimab and imdevimab.
From January to August 2021, participants received the antibodies as a single infusion. Their outcomes were compared to breakthrough COVID-19 patients who did not receive antibodies.
The hospitalization rate was 2.7 percent among patients who received antibodies, compared to 10.7 percent among those who did not receive treatment.
The participants’ average age was 54, and about 10 percent were cancer patients.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.